About 22 million adults in the United States have metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH) — a liver condition that causes inflammation and damage like scarring (fibrosis), cirrhosis or liver failure.  

However, the recent U.S. Food and Drug Administration (FDA) approval of Novo Nordisk’s semaglutide (Wegovy) for treating MASH is providing new hope for patients, whose only other currently approved treatment option is resmetirom (Rezdiffra) from Madrigal Pharmaceuticals with a list price of $49,391 a year.¹   

In the latest episode of the “Pharmacy Friends” podcast, join host Maryam Tabatabai, PharmD, associate vice president of clinical information at Prime Therapeutics (Prime); Olivia Pane, PharmD, CDCES, drug information pharmacist; Edmundo Rodriguez-Frias, M.D., physician clinical reviewer; and Katie Lockhart, senior manager of analytics, as they unpack Prime’s newest clinical report on a silent but serious condition.  

“The end goal for us is, of course, to provide the best possible care for patients, and MASH care is no exception to that,” Pane said. “So it’s important that payers and providers stay up to date with these new and emerging therapies so that the best and most cost-effective treatments can be chosen for each patient.” 

Listeners will gain a deeper understanding of the clinical significance and growing impact of MASH and what evolutions in treatment mean for patients, providers and the future of liver health.  

“Pharmacy Friends” is a podcast dedicated to bringing industry experts to the same table to talk about what is happening in pharmacy today, what is coming and, most importantly, what it means to you. Listen to the full episode “New Era in Liver Health: GLP-1s and the MASH Breakthrough” at PrimeTherapeutics.com/Listen.    

Read the latest clinical insights report  

Learn more about Prime’s GLP-1 strategy 

References

1. DrugIQ Drug Search. Accessed August 7, 2025.